TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics has announced significant changes to its Board of Directors as it prepares for its next phase of growth, particularly advancing towards Phase 3 clinical development. Founding shareholder and former CEO Geoffrey Kempler is retiring, marking the end of a transformative era for the company. Brian Meltzer, a long-serving director, is also retiring. The company has appointed Dr. David Stamler as Managing Director and CEO, and Julian Barbaczy as Non-Executive Chair, both bringing extensive experience to support Alterity’s strategic vision and late-stage clinical development. These changes are aimed at ensuring continuity of governance and supporting the company’s drive towards meaningful outcomes for patients and shareholders.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative diseases. It has built a strong intellectual property portfolio and is advancing its lead clinical asset, ATH434, towards Phase 3 development for Multiple System Atrophy, a Parkinsonian disorder with no approved therapy.
Average Trading Volume: 14,942,225
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.